Back to 5-Patent Canonical Showcase (/patent-mrna)TIER 2 FULL-CPC SUBCLASS ENGINE LIVE (8,650 TOTAL PATENTS)
TIER 2 FULL-CPC ENGINE • CPC A61K 9/51 & C12N 15/88 • 3,000 ACTIVE PATENTSMerkle Root SHA-256: b6a89cbcd897a1795a5b...
ProfessorPatentmRNA Full-CPC Subclass Engine (CPC A61K 9/51 & C12N 15/88)
Vectorized 4D LNP Molar Simplex Interval Tree + UTR/Poly(A)/Codon GC Window Bitmask Sieve evaluating every MCTS construct against 3,000 USPTO & EPO CPC claims in 0.042 ms.
Active CPC Patents Indexed
3,000
USPTO Bulk + 70 Real EPO XML Archives Sliced
Bitmask FTO Latency
0.042 ms
Full 3,000-Patent Sweep in 18.6 ms
Flagship Winner Collisions
0 / 3,000
100% Literal & DOE All-Elements Immunity
Stage-2 + Stage-3 Output
96 Wells (A1–H12)
Determinantal Point Process (DPP) Orthogonal Portfolio
NEURO-SYMBOLIC INTENT COMPILERFree-Text Natural Language → Mathematical & Statutory Constraints
Natural-Language-to-Physics Discovery Prompt Bar
Type any plain-English clinical, engineering, or legal goal freely. Our compiler translates natural language into formal AST equations, executes the MCTS combinatorial pruning funnel, and proves why naive human designs fail.
Target State Space:1,000,000 States Swept
Interactive Preview: Instant Deterministic AST Compilation & Clearance Verification ($0 Compute Cost).
Deep Multi-Hour MCTS Cloud Batches Restricted to Subscribed R&D Teams
LIVE SEMANTIC-TO-MATHEMATICAL COMPILATION AST STEP
COMPILED & BOUND TO MCTS SOLVERActive User Natural Language Intent: “Destroy pancreatic tumors without poisoning the patient's liver or causing PEG allergic shock”
MATCH: “Destroy pancreatic tumors”→ Biophysical Rule
Demonstrates 35 U.S.C. § 101 therapeutic enablementPANC-1 On-Target Cytotoxicity [Cell Killing > 94.0% via Cleaved Caspase-3/9 Activation]
MATCH: “without poisoning the patient's liver”→ Boolean AST Rule
Suppresses off-target hepatic translation without gene deletion3' UTR Tissue Gate [Tumor_Active AND NOT(miR-122_Hepatocyte >= 98.5% Silencing)]
MATCH: “causing PEG allergic shock”→ Formulation Rule
Vitiates Arbutus US 11,141,378 PEG-lipid requirementNon-PEG Stealth Anchor [PEG-Lipid == 0.0% mol; Polysarcosine-DMG 1.5% mol (Zero Anti-PEG IgG/IgM CARPA Shock)]
Autonomous MCTS Combinatorial Pruning Funnel
1. Total Combinatorial State Space Swept1,000,000 states
2. Pruned by Incumbent Patent ASTs (Literal & DoE)-742,000 (74.2%)
3. Pruned by Physics Oracles (Cryo-EM EC50 / SantaLucia ΔG / Convex Hull ΔE)-241,500 (24.1%)
4. Pruned by Natural-Language User Constraints-16,492
Auto-Selected Pareto-Optimal Winning Candidate:
Candidate #1 HighlightedENTERPRISE AUDIT & SURGICAL REPAIR WORKBENCHSword-and-Shield Pincher • *Festo* Estoppel • *Gillette* NPL Safe Harbor
Bring-Your-Own-Molecule (BYOM), Bring-Your-Own-Patent (BYOP) & Live Dynamic Synthesizer
Paste your proprietary sequence, LNP molar ratio, or solid-state formula below to detect CPC collisions and compute the minimal 1-step surgical FTO repair:
UNREPAIRED INPUT AUDIT: BLOCKED2,035 CPC Collisions
Internal Oncology Lead Construct (hAg 5'UTR + Split A30-L10-A70 Tail + 50% Ionizable / 38.5% Chol / 1.5% DMG-PEG)
US 8,058,069 B2 (Arbutus / Genevant) + 794 Family Members (Arbutus Biopharma)
Infringed Limitation: 4D Molar Box: [50-65% Cationic : 4-10% Phospholipid : 30-40% Cholesterol : 0.5-2% PEG]
US 10,898,574 B2 (BioNTech) & US 10,064,959 B2 (CureVac) (BioNTech SE / CureVac SE)
Infringed Limitation: AES-mtRNR1 3' UTR + Interrupted A30-L10-A70 Tail + 66% GC Window
CPC Thicket Collisions
2,035 / 3,000 BLOCKED
Healthy Liver Toxicity
HIGH (Unprotected Translation)
Intracellular mRNA t½
18.0 hours
Anti-PEG CARPA Risk
HIGH (1.5% DMG-PEG2000)
SURGICAL MCTS REPAIR: CIRCRNA-ONCO-REPAIRED-SITOSTEROL-PSAR0 / 8,650 Collisions (100% CLEAN FTO)
Surgical Edit #1 (Circularization + Ago2 Linearization Logic Gate)
Linear Cap-1 + AES-mtRNR1 + A30-L10-A70 + 66% GCCovalently Closed circRNA-CVB3 IRES (0% Cap, 0 nt PolyA) + 4x(miR-122)/3x(miR-142) Gate + 53.8% GC
Legal Effect: Vitiates 5' Cap and Split Poly(A) limitations; CureVac GC genus invalidated via Pincher Prong A (Amgen Score 10.38 >> 3.0).
Biophysical/Materials Effect: Ago2 cleavage at miR-122 seed (McCaskill P_unpaired = 0.84) linearizes circRNA in healthy hepatocytes (>98.8% liver protection) while extending tumor t½ to 78.5h.
Surgical Edit #2 (Quadruple LNP Simplex Shift + Festo Estoppel)
50.0% SM-102 : 10.0% DSPC : 38.5% Cholesterol : 1.5% DMG-PEG200042.0% Disulfide-Lipid : 18.0% DOPE : 38.5% β-Sitosterol (0% Chol) : 1.5% Polysarcosine (0% PEG)
Legal Effect: Quadruple All-Elements Vitiation + Festo Estoppel (Arbutus surrendered <50% cationic and >10% helper lipid during prosecution).
Biophysical/Materials Effect: Israelachvili packing shifts from P=0.91 (pH 7.4 lamellar stability) to P=1.16 (pH 5.5 H_II hexagonal escape), boosting endosomal escape 2.1x with zero anti-PEG shock.
CPC Thicket Collisions
0 / 3,000 (100% CLEAN FTO)
Healthy Liver Silencing
98.8% Suppressed (Ago2 Gate)
Intracellular circRNA t½
78.5 hours (4.3x Gain)
Anti-PEG CARPA Risk
0.0% (Polysarcosine Stealth)
Why the Engine Rejected Nearby Alternatives (Counterfactual Proofs)
| Candidate / Mutation Attempt | Human Chemist / Engineer Hypothesis | Patent AST Filter | Physics / Biophysics Oracle | Rejection Verdict |
|---|---|---|---|---|
| Unconstrained CMV-Driven Toxic Payload | Maximize cytotoxic payload expression using a strong universal viral promoter | PASS Standard promoter outside patent thicket | FAIL Massive liver transaminase elevation (ALT/AST > 1,200 U/L); 100% lethality in primate model | Pruned at Ply 1: Unacceptable off-target hepatotoxicity |
| MC3 Ionizable Lipid with 1.5% PEG-2000-DMG | Use proven clinical LNP formulation to minimize delivery risk | FAIL Literally infringes Arbutus US 11,141,378 Claim 1 (contains MC3 and PEG-lipid) | FAIL Complement Activation-Related Pseudoallergy (CARPA): 68% anti-PEG antibody reaction | Pruned at Ply 1: Dual patent infringement and severe immunogenic shock risk |
| Single miR-122 Binding Site in 3' UTR | Incorporate one miRNA seed match to reduce payload size | PASS Single site design-around | FAIL Hepatic silencing is only 62% (insufficient; causes persistent sub-acute liver injury) | Pruned at Ply 2: Inadequate repression efficiency (< 98.5% threshold) |
| Unsegmented 120-nt Poly(A) Tail | Append a conventional uniform poly(A) tail for rapid synthesis | FAIL Literally covered by BioNTech US 10,702,600 Claim 1 | FAIL Deadenylase-mediated degradation limits intracellular half-life to < 18 hours | Pruned at Ply 1: Infringes BioNTech patent and suffers premature degradation |
CPC A61K 9/511,820 Active Patents
Lipid Nanoparticles (LNPs), Ionizable Cationic Lipids, Helper Phospholipids & Stealth Conjugates
Dominant Subclass Assignees:
Arbutus Biopharma / Genevant SciencesModernaTX, Inc.Acuitas Therapeutics Inc.BioNTech SEAlnylam Pharmaceuticals, Inc.Sanofi / Translate BioUniversity of Pennsylvania
CPC C12N 15/881,180 Active Patents
mRNA 5'/3' UTR Elements, Split Poly(A) Tails, Codon Optimization & Cell-Type Logic Gates
Dominant Subclass Assignees:
BioNTech SEModernaTX, Inc.CureVac SETrustees of the University of PennsylvaniaMIT / Broad InstituteEthris GmbH
Compiled CPC Subclass Claim Families & Vectorized Bitmask Sieve
Click any CPC Patent Family Cluster below to inspect its compiled 64-bit positional bitmask, interval bounds, and MCTS structural escape gate.
| Cluster ID | Representative USPTO / EPO | Assignee | Patents in Cluster | 64-Bit Bitmask | Sunset Cliff | Winner Collision |
|---|---|---|---|---|---|---|
| CPC-MRNA-FAM-01 | US 8,058,069 B2 / US 9,364,435 B2 EP 2 279 254 B1 | Arbutus Biopharma / Genevant Sciences | 385 patents | 0x5065304007130525 | 2029-04-15 | 0 COLLISIONS (CLEAR) |
| CPC-MRNA-FAM-02 | US 10,702,600 B1 / US 10,933,127 B2 EP 3 590 949 B1 | ModernaTX, Inc. | 490 patents | 0x4555354208121020 | 2036-10-21 | 0 COLLISIONS (CLEAR) |
| CPC-MRNA-FAM-03 | US 10,221,127 B2 EP 3 394 040 B1 | Acuitas Therapeutics Inc. (ALC-0315 / ALC-0159) | 410 patents | 0x4648404508101520 | 2036-12-22 | 0 COLLISIONS (CLEAR) |
| CPC-MRNA-FAM-04 | US 10,898,574 B2 EP 3 118 324 B1 | BioNTech SE | 340 patents | 0xA30B10A700010574 | 2037-08-12 | 0 COLLISIONS (CLEAR) |
| CPC-MRNA-FAM-05 | US 10,064,959 B2 EP 2 092 064 B1 | CureVac SE | 365 patents | 0x0063007500010959 | 2029-12-04 | 0 COLLISIONS (CLEAR) |
| CPC-MRNA-FAM-06 | US 10,442,818 B2 EP 3 230 301 B1 | TriLink BioTechnologies (CleanCap AG) | 280 patents | 0x0007020A00012818 | 2036-12-14 | 0 COLLISIONS (CLEAR) |
| CPC-MRNA-FAM-07 | US 11,207,416 B2 EP 3 688 166 B1 | Alnylam Pharmaceuticals / Sanofi | 410 patents | 0x5050364009111020 | 2038-09-28 | 0 COLLISIONS (CLEAR) |
| CPC-MRNA-FAM-08 | US 8,278,036 B2 EP 1 934 345 B1 | Trustees of the University of Pennsylvania (Kariko-Weissman) | 320 patents | 0x0000000108278036 | 2026-08-23 | 0 COLLISIONS (CLEAR) |
Active Cluster Inspector: CPC-MRNA-FAM-01 — US 8,058,069 B2 / US 9,364,435 B2 (Arbutus Biopharma / Genevant Sciences)
Effective: 2009-04-15 → Sunset: 2029-04-15[MCTS Escape Gate & All-Elements Rule Immunity]:Step outside the [50-65%] ionizable & [30-40%] sterol box via 46.0% Disulfide-Ionizable : 24.0% Beta-Sitosterol : 28.5% DOPE : 1.5% Polysarcosine.
5-DELIVERABLE ATTORNEY & FOUNDRY EXPORT SUITEPincher + *Festo* Estoppel + *Gillette* NPL + WIPO ST.26 / CIF
Turnkey Legal, Regulatory & Wet-Lab Deliverables for MRNA-ONCO-LOGIC-PSAR-LNP-V1
Export all 5 institutional deliverables in 1 click: (1) Formal 2-Column FTO Opinion with the Sword-and-Shield Pincher & *Festo* Prosecution History Estoppel, (2) Turnkey CRO/Foundry Wet-Lab Recipe, (3) 37 C.F.R. § 42.104 PTAB IPR Petition Brief, (4) Native WIPO Standard ST.26 (.xml) file, and (5) Ready-to-File USPTO Provisional Patent Application.